



## LJMU Research Online

**Davis, NL, Tolfrey, K, Jenney, M, Elson, R, Stewart, CE, Moss, AD, Cornish, JM, Stevens, MCG and Crowne, EC**

**Combined resistance and aerobic exercise intervention improves fitness, insulin resistance and quality of life in survivors of childhood haemopoietic stem cell transplantation with total body irradiation**

<http://researchonline.ljmu.ac.uk/id/eprint/13915/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Davis, NL, Tolfrey, K, Jenney, M, Elson, R, Stewart, CE, Moss, AD, Cornish, JM, Stevens, MCG and Crowne, EC (2020) Combined resistance and aerobic exercise intervention improves fitness, insulin resistance and quality of life in survivors of childhood haemopoietic stem cell transplantation with total**

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>



*Exercise intervention paper final version PBC*

1 **Combined Resistance and Aerobic Exercise Intervention Improves Fitness, Insulin**  
2 **Resistance, and Quality of Life in Survivors of Childhood Haemopoietic Stem Cell**  
3 **Transplantation With Total Body Irradiation**

4

5 Dr Nikki L Davis, Keith Tolfrey, Meriel Jenney, Ruth Elson, Claire Stewart, Andrew D  
6 Moss, Jacqueline M Cornish, Michael CG Stevens, Elizabeth C Crowne.

7

8 Affiliation and addresses of authors

9 Nikki Davis, Department of Paediatric Endocrinology and Diabetes, University Hospitals  
10 Bristol & Weston NHS Foundation Trust, Level 6 UHBristol Education Centre, Upper  
11 Maudlin Street, Bristol, BS2 8AE

12 Keith Tolfrey, Paediatric Exercise Physiology Group, School of Sport, Exercise and  
13 Health Sciences, Loughborough University, Loughborough, Leicestershire, LE11 3TU.

14 Meriel Jenney, Children's Hospital for Wales, Heath Park, Cardiff, CF14 4XW.

15 Ruth Elson, Department of Paediatric Oncology, University Hospitals Bristol & Weston  
16 NHS Foundation Trust, Bristol Royal hospital for Children Upper Maudlin Street,  
17 Bristol, BS2 8BJ.

18 Claire Stewart, Research Institute for Sport and Exercise Science, Liverpool John Moores  
19 University, Life Sciences Building, Byrom Street, Liverpool, L3 3AF.

20 Andrew D Moss, Research Institute for Sport and Exercise Science, Liverpool John  
21 Moores University, Tom Reilly Building, Byrom Street, Liverpool, L3 3AF.

22 Jacqueline M Cornish, Department of Paediatric Oncology, University Hospitals Bristol  
23 & Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8AE.

*Exercise intervention paper final version PBC*

24 Michael CG Stevens, Translational Health Sciences, Bristol Medical School, University  
25 of Bristol, Bristol BS8 1UD

26 Corresponding author: Dr Elizabeth Crowne, Department of Paediatric Endocrinology  
27 and Diabetes, University Hospitals Bristol & Weston NHS Foundation Trust, Level 6

28 UHBristol Education Centre, Upper Maudlin Street, Bristol, BS2 8AE. Email:

29 [liz.crowne@uhbw.nhs.uk](mailto:liz.crowne@uhbw.nhs.uk). Tel: 0117 342 0165 Fax: 0117 342 0186 Mob: 07702

30 891974

31

32 Word Count: Abstract 248 (target <250); Main Text 3499 (target <3500)

33

34 Number of tables: 2

35 Number of figures: 3

36

37 Keywords: Exercise; Haemopoietic stem cell transplantation; Total body irradiation;

38 Growth hormone; Insulin resistance.

39

40 Short running title: Exercise intervention after HSCT/TBI

41

42 **Abbreviations table:**

Abbreviation	Full term or phrase
QoL	quality of life
HSCT	haemopoietic stem cell transplantation
TBI	total body irradiation
DEXA	dual energy X-ray absorptiometry
HOMA-IR	homeostatic model assessment of insulin resistance
$\dot{V}O_{2peak}$	peak rate of oxygen uptake
SF-36	36-Item Short Form Health Survey
SD	standard deviation
MMQL	Minneapolis-Manchester Quality of Life Instrument
GHD	growth hormone deficiency
GH	growth hormone
PRT	progressive resistance training programme
CNS	central nervous system
GVHD	graft versus host disease
ITT	insulin tolerance test
BMI	body mass index
BMISDS	body mass index standard deviation score
ECHO	echocardiogram
FVC	forced vital capacity

*Exercise intervention paper final version PBC*

FEV1	forced expiratory volume in first second
SDS	standard deviation score
VT	ventilation threshold
Pulse O <sub>2</sub>	the rate of oxygen uptake per heart beat ( $\dot{V}$ O <sub>2</sub> /heart rate (HR))
HR	heart rate
RER	respiratory exchange ratio
ANOVA	one-way withinrepeated measures analysis of variance
FVCSDS	forced vital capacity standard deviation score
LSD	post-hocFisher's least significance difference method
GLUT-4	glucose transporter protein
AMPK	AMP-activated protein kinase
Akt	protein kinase B substrate
T2DM	type 2 diabetes mellitus
HRT	hormone replacement therapy

43

44

45

*Exercise intervention paper final version PBC*

## 46 Abstract

47 **Purpose:** To investigate the effects of a supervised combined resistance and aerobic  
48 training programme on cardiorespiratory fitness, body composition, insulin resistance and  
49 quality of life(QoL) in survivors of childhood hematopoietic stem cell  
50 transplantation(HSCT) with total body irradiation(TBI).

51 Participants: HSCT/TBI survivors( $n=20$ ; 8 Female). Mean(range) for age at and time  
52 since HSCT/TBI was 16.7(10.9-24.5) and 8.4(2.3-16.0)yrs respectively.

53 **Methods:** After a 6-month run-in, participants undertook supervised 45-60-minute  
54 resistance and aerobic training twice-weekly for 6 months, with a 6-month follow-up.  
55 The following assessments were made at 0, 6(start of exercise programme), 12(end of  
56 exercise programme) and 18 months: Body composition via dual energy X-ray  
57 absorptiometry(DEXA), homeostatic model assessment of insulin resistance(HOMA-IR),  
58 cardiorespiratory fitness(treadmill based peak rate of oxygen uptake( $\dot{V}O_2$ peak) test), QoL  
59 questionnaires(36-Item Short Form Health Survey(SF-36) and Minneapolis-Manchester  
60 Quality of Life Instrument(MMQL).

61 **Results:** Results expressed as mean(SD) or geometric mean(range). There were  
62 significant improvements in  $\dot{V}O_2$ peak(35.7(8.9)vs.41.7(16.1)mL/min/kg,  $P=0.05$ ), fasted  
63 plasma insulin(16.56(1.48-72.8)vs.12.62(1.04-54.97)mIU/L,  $P=0.03$ ), and HOMA-  
64 IR(3.65(0.30-17.26)vs.2.72(0.22-12.89),  $P=0.02$ ) after the exercise intervention. There  
65 were also significant improvements in the SF-36 QoL general health  
66 domain(69.7(14.3)vs.72.7(16.0),  $P<0.001$ ) and the MMQL school domain  
67 (69.1(25.2)vs.(79.3(21.6),  $P=0.03$ ) during the exercise intervention. No significant  
68 changes were observed in percentage body fat, fat mass or lean mass.

*Exercise intervention paper final version PBC*

69 **Conclusion:** The supervised 6/12 combined resistance and aerobic exercise programme  
70 significantly improved cardiorespiratory fitness, insulin resistance and QoL in childhood  
71 HSCT/TBI survivors, with no change in body composition, suggesting a metabolic  
72 training effect on muscle. These data support a role for targeted physical rehabilitation  
73 services in this group at high risk of diabetes and cardiovascular disease.

74



**75 Introduction**

76 HSCT with TBI has significantly improved survival in childhood leukaemia but is  
77 associated with important long-term sequelae<sup>1 2</sup>. Survivors demonstrate central  
78 adiposity<sup>3</sup>, reduced lean mass<sup>4</sup>, and risk factors for the metabolic syndrome<sup>5</sup> including  
79 increased blood pressure<sup>1</sup>, dyslipidaemia<sup>5</sup>, insulin resistance, diabetes<sup>6 3</sup>, and impaired  $\beta$ -  
80 cell function<sup>7</sup>. Growth hormone deficiency (GHD) after TBI also predisposes to these  
81 morbidities but they persist despite growth hormone (GH) treatment<sup>8</sup>.

82 QoL in HSCT survivors is variable and whilst longer term studies are still needed in  
83 children<sup>9</sup>, adults experience physical, cognitive and social difficulties, and fatigue<sup>2 10</sup>.  
84 Children with leukemia have reduced physical fitness, partly due to inactivity<sup>10 11</sup>, but  
85 exercise has shown benefit, including to children after HSCT<sup>12 13 14 15</sup>. More generally,  
86 exercise programmes improve cancer treatment related fatigue and QoL<sup>17 18 19</sup>.

87 Aerobic activity is the most commonly used intervention for reducing cardiovascular  
88 risk<sup>16</sup>, and reduces visceral fat<sup>17</sup>, insulin resistance<sup>18</sup>, and blood pressure<sup>19 20</sup> in both  
89 adults and children. Progressive resistance training (PRT) also confers improvement in  
90 cardiovascular risk<sup>20 21 22</sup>, and is becoming more widely utilised with potential benefit in  
91 increasing lean body mass<sup>23 24</sup> of particular relevance to HSCT/TBI survivors<sup>25</sup>.

92 HSCT/TBI survivors therefore have a range of factors which may benefit from exercise  
93 rehabilitation including PRT. Our aim was to conduct a supervised combined aerobic and  
94 PRT in childhood survivors of HSCT/TBI, to examine effects on fitness, body  
95 composition, insulin resistance, and QoL.

**96 Method**

97 **Ethical Approval:** This study was conducted in accordance with the Declaration of  
98 Helsinki following approval by the NHS South West Frenchay Research Ethics  
99 Committee. Written informed consent was obtained from all participants.

100 **Participants:** Children/adolescents followed up after HSCT/TBI for haematological  
101 malignancy at a single regional centre between 1993-2004 were identified via the  
102 endocrine database and the Leukaemia registry. Eligible participants were those on GH  
103 replacement for GHD (to control for GH status)<sup>26 27</sup>. Participants were approached by  
104 their late effects team and 24 consented to participate. All were >1 year post-HSCT/TBI  
105 or any oncology or steroid treatment.

106 All were on GH treatment for >6months before study enrolment, for GHD diagnosed by  
107 standard insulin tolerance test (ITT) after documentation of poor growth. Demographic  
108 and oncology treatment data of participants are shown in Table 1.

109 **Study Design:** A within-subject longitudinal repeated measures study, frequently used in  
110 Sports science research<sup>28</sup>. Baseline data collection was performed at study entry (time1)  
111 and after a 6-month period of habitual activity and GH treatment (time2) to assess  
112 changes over time not attributable to the subsequent exercise intervention. A 6-month  
113 supervised aerobic and PRT followed with data collection at the end of the intervention  
114 (time3) and again, after a further 6-months (time4).

115 **Data Collection:** At each time point included auxology, body composition assessment  
116 with DEXA, HOMA-IR, cardiorespiratory fitness  $\dot{V}O_2$ peak test, and QoL questionnaires  
117 (SF-36 and MMQL).

*Exercise intervention paper final version PBC*

118 **Auxology:** Height was measured to the nearest mm using a wall-mounted Harpenden®  
119 stadiometer (Holtain, Crymych, UK) calibrated daily, body weight to the nearest 0.1kg  
120 using a single set of scales (Seca®, Hamburg, Germany), both using standard auxology  
121 procedures<sup>29</sup>. Pubertal status was assessed using standard Tanner staging<sup>30</sup>, by a single  
122 observer (ND). For males, only pubic hair and virilisation of the external genitalia were  
123 used, as testicular volume is not a reliable marker of puberty due to sertoli cell damage.  
124 Body mass index (BMI) was calculated as weight/height<sup>2</sup>(kg/m<sup>2</sup>) and converted to body  
125 mass index standard deviation score (BMISDS) using Cole's method<sup>31</sup>.

126 **Body Composition:** DEXA fan-beam technique (Lunar Prodigy DF+15048 series, GE  
127 Healthcare, Madison, Wisconsin, USA) was used to differentiate whole body fat, lean  
128 mass, and percentage trunk fat.

129 **QoL questionnaires:** All participants (those <16 years with parental assistance)  
130 completed SF-36, a generic health related QoL measure for adults with chronic disease  
131 including cancer survivors<sup>32</sup> and those with GHD<sup>33</sup>. The SF-36 is well validated, widely  
132 used, and comprises 36 questions on general health and well-being during the previous 4  
133 weeks. Data are presented as T scores i.e. are normalised with mean(SD) of 50(10).  
134 Higher scores indicate better quality of life. One or more SDs below the population mean  
135 demonstrates poor QoL. MMQL is a specific measure for childhood cancer survivors <18  
136 years, demonstrated to show validity and reliability, with versions for youth, adolescents,  
137 and parents and carers of children. It is a comprehensive, multidimensional self-report  
138 instrument across 5 scales including physical, emotional, social, school and body image.  
139 It is the only questionnaire assessing satisfaction with appearance, potentially an  
140 important aspect for childhood cancer survivors<sup>34</sup>. Previous studies have shown that

*Exercise intervention paper final version PBC*

141 childhood cancer survivors show similar overall QoL to controls with mean scores of 4/5  
142 or 80%<sup>34</sup>.

143 **Assays:** Laboratories were Clinical Pathology Accredited. Plasma samples for glucose  
144 were assayed within 4hrs (Olympus AU640 or AU2700 clinical chemistry analyser,  
145 Olympus, Hamburg, Germany). A commercially available ELISA kit (Human Insulin  
146 KAP1251 (MDC 0.15µIU/mL and CV 5.3%), BioSource Europe S.A., Nivelles,  
147 Belgium) was used to determine plasma insulin concentrations. The maximum time to  
148 assay was 24 months using plasma/serum samples frozen at -80°C.

149 **HOMA-IR:** Venous blood (3mL), collected between 08:00 and 10:00 following  
150 overnight fasting for 8 to 12 hr were analysed for plasma glucose and insulin  
151 concentrations. HOMA-IR was calculated as: fasted plasma insulin concentration(mIU/L)  
152 x fasted plasma glucose concentration(mmol/L)/22.5<sup>35</sup>.

153 **Exercise intervention:** Participants were required to perform 45-60 minutes of exercise  
154 at least twice, but preferably three times per week. KT, an exercise physiologist  
155 experienced in training children and young people and special groups, designed the  
156 generic programme, which was supervised by ND and local gym trainers with  
157 appropriate qualifications for children and young people to ensure individual participant  
158 safety. ND monitored attendance and progress. Patient feedback and study retention  
159 demonstrated that the participants enjoyed the exercise programme and found it valuable.  
160 In order to minimise the potential for an adverse cardiac event, each participant  
161 underwent an echocardiogram (ECHO), conducted and assessed by a cardiologist before  
162 proceeding with the intervention. All received an induction programme and were  
163 supervised at every session. They were asked to perform at least 15 minutes of self-

*Exercise intervention paper final version PBC*

164 selected aerobic activity at moderate intensity (60-70% of maximum HR) followed by  
165  $\geq 30$  minutes of PRT using body weight or standard machine-based PRT equipment and  
166 involving at least 9 major muscle groups, at resistance loads of 60-80% 1RM. The  
167 programme involved a standard range of flexion and extension exercises tailored to the  
168 individual. Initially, participants performed 1 set of 18-20 repetitions, progressing over 6-  
169 months to 3 sets of 10-12 repetitions for each muscle group. This approach minimised  
170 lean tissue loss initially, and maximised the likelihood of safe gains in lean mass. At  
171 baseline and every 6 weeks, 1 repetition maximum (1RM) strength tests (leg press and  
172 chest press) were undertaken by qualified instructors to monitor gains in skeletal muscle  
173 strength.

174 Isometric exercise was avoided due to the risk of cardiomyopathy from TBI and  
175 anthracycline toxicity.

176 **Exercise test outcome measurements:** Forced vital capacity (FVC) and forced  
177 expiratory volume over the first second (FEV1) were measured using spirometry. Results  
178 were expressed as standard deviation scores (SDS) adjusted for age, gender and stature<sup>36</sup>.  
179 A modified Balke 2 protocol was used<sup>37</sup> to measure  $\dot{V}O_2$ peak; participants walked/jogged  
180 on a motorised treadmill belt with incremental changes in speed and inclination every  
181 two minutes until volitional exhaustion. Respiratory data collected including the rates of  
182 oxygen uptake and carbon dioxide elimination ( $\dot{V}CO_2$ ).  $\dot{V}O_2$ peak is traditionally  
183 expressed either in absolute terms (L/min) or relative to body mass (mL/min/kg), the  
184 latter assuming a constant relationship between lean mass and fat mass<sup>38</sup>. It is  
185 conventional to express measured  $\dot{V}O_2$ peak data relative to body mass<sup>39</sup> when comparing  
186 with published normal data for age and gender<sup>40</sup> and absolute  $\dot{V}O_2$ peak values were

*Exercise intervention paper final version PBC*

187 divided by body weight to yield relative data. The ventilatory threshold (VT) was  
188 assessed by the V-slope method<sup>41</sup> and refers to the point where aerobic metabolism is  
189 supplemented by anaerobic mechanisms during progressive exercise, and can be  
190 expressed as occurring at a percentage of  $\dot{V}O_2$  peak. Pulse  $O_2$  is the rate of oxygen uptake  
191 per heart beat ( $\dot{V}O_2$ /heart rate (HR)) and is a measure of circulatory efficiency increasing  
192 with stature, and therefore age, in childhood. Respiratory exchange ratio (RER) is the  
193 ratio  $\dot{V}CO_2/\dot{V}O_2$ . Peak exercise tests were considered truly at peak if at least two of the  
194 following criteria were satisfied: a plateau ( $\leq 2$  mL/min/kg) in the  $\dot{V}O_2$  profile over the  
195 final two exercise stages, HR  $\geq 95\%$  age-predicted maximum (220beats/min –  
196 chronological age) and/or RER  $\geq 1.10$ . Exercise test outcome measures were  $\dot{V}O_2$ ,  $\dot{V}CO_2$ ,  
197 VT, Pulse  $O_2$  and HR.

198 **Statistical analyses:** Statistical analyses were performed using IBM SPSS version 17.0  
199 (IBM Corporation, New York, USA). Statistical significance was accepted at  $P \leq 0.05$ .  
200 Normally distributed data were expressed as mean(SD). Skewed data were expressed as  
201 geometric mean(range) and log-transformed(log10) to normalise the distribution and  
202 facilitate the correct use of parametric statistical testing for between time comparisons.  
203 Parametric data were compared overall using repeated measures analysis of variance  
204 (ANOVA) followed by pairwise comparisons using the post-hoc Fisher's least  
205 significance difference (LSD) method. As there were randomly missing data points, a  
206 repeated measures analysis using the 'SAS mixed procedure' was used for between time  
207 comparisons using ANOVA. This method uses a maximum likelihood method and  
208 automatically excludes missing data by using mixed modelling. In this data the strength  
209 of correlations between data at different time points did not vary significantly.

*Exercise intervention paper final version PBC*

210 Proportions were compared using Chi-square or Fishers Exact tests when appropriate for  
211 smaller sample sizes.

**212 Results**

213 Twenty-four participants consented to the study and 20(8 females:12 males) completed  
214 the supervised combined aerobic and PRT. Exercise diaries demonstrated 85% attended  
215 at least twice weekly and 35% attended 3 times weekly over the 6-month period): 4 were  
216 unable to complete the intervention (sickness =2; time constraints =2). Sixteen completed  
217 post-exercise intervention data collection (4 unavailable due to relocation out of region).  
218 None had conditions which precluded exercise; 6 had reduced fractional shortening on  
219 ECHO attributed to subclinical anthracycline toxicity.

**220 Baseline data (time1)**

221 **Cardiorespiratory fitness:** Six participants displayed forced vital capacity standard  
222 deviation score (FVCSDS) <-3 suggesting restrictive lung deficits with mean maximal  
223 ventilation (FVCx40) reduced to <75% expected in healthy young people. However, as  $\dot{V}$   
224  $O_2$  is the rate-limiting step, maximal ventilation is not usually reached during an exercise  
225 test. Peak ventilation as a proportion of the predicted maximal ventilation (FVCx40) was  
226 mean(SD) 58.6(18.8)%. Only one patient exercised at maximal ventilatory capacity with  
227 a FVCSDS of -5.78.

228  $\dot{V}O_{2peak}$  divided by body mass was reduced at baseline (mean 35.7mL/min/kg)  
229 compared to published normal values for age and sex (females 39-45mL/min/kg and  
230 males 49-50mL/min/kg)<sup>40</sup>.

231 **Body Composition:** Female participants had significantly higher body fat and trunk fat  
232 than males: female body fat mean(SD) 41.7(8.2)%vs.male 24.3(13.5)%, $P<0.001$ ; female

*Exercise intervention paper final version PBC*

233 trunk fat 42.8(10.7)%vs.male 24.7(14.0)%, $P=0.004$ ). Female participants also had higher  
234 body fat than published UK normal data for females of the same age<sup>42</sup>. HOMA-IR values  
235 were greater (mean(range) 3.65( 0.30-17.26)) than the published upper limit of normal  
236 (2.0= mean plus 2 SD)<sup>43</sup>. Sex differences were apparent in both fasted plasma insulin and  
237 HOMA-IR values, with higher levels in females: fasted plasma insulin mean (range) 25.0  
238 (6.5-50.0)vs.9.5 (2.6-68.3) $\mu$ IU/mL, $P=0.013$ ; HOMA-IR mean(range) 5.0(1.3-  
239 11.1)vs.2.2(0.5-18.3), $P=0.047$ .

**240 Baseline data (time2)**

241 **End of run in period:** There were no changes in cardio-respiratory fitness, body  
242 composition or insulin resistance during the run-in period (see Table 2) when participants  
243 were engaging in their usual level of habitual activity.

**244 Impact of Exercise Intervention (times2-3)**

245 **Body composition and insulin resistance:** There were no significant changes in fat  
246 mass, lean mass or percentage body fat (Table 2) but significant improvements in  
247 markers of insulin resistance such as fasted plasma insulin concentrations ( $P=0.026$ ) and  
248 HOMA-IR ( $P=0.024$ ) following the exercise intervention, and maintained at  
249 time3vs.4( $P=0.60$  and  $P=0.06$ ) respectively (Table 2, Figure 2).

250 **Cardiorespiratory fitness:** There were significant improvements in  $\dot{V}O_2$   
251 peak(mL/min/kg) (time2vs.3), which were maintained at time3vs.4( $P=0.05$ ) (Table 2,  
252 Figure 1). There were no further improvements during the follow-up period (time3vs.4)  
253 when participants were not in a formal exercise programme. Pulse  $O_2$  increased  
254 significantly with training ( $P=0.026$ ). VT occurred at mean(SD) 72.0(11.9)% $\dot{V}O_2$ peak  
255 and did not change with training. Significant gains in strength were identified from 1RM



*Exercise intervention paper final version PBC*

256 testing: mean(SD) 81.5(40.4)%, $P<0.001$  increase in leg strength and  
257 90.4(78.9)%, $P<0.001$  increase in chest strength.

258 **QoL:** There were significant improvements in the SF-36 QoL general health domain  
259 during the exercise intervention: mean(SD)(69.7(14.3)vs.72.7(16.0), $P<0.001$ ), which  
260 were maintained at time3vs.4, $P<0.05$  (Figure 3). Data from the SF-36 QoL questionnaire  
261 identified significant improvements before the exercise intervention in physical health  
262 (85.2(13.8)vs.91.5(11.4), $P=0.007$ ); physical role (84.1(17.7)vs.94.4(9.5), $P=0.012$ );  
263 emotional role (80.9(22.2)vs.91.3(16.6), $P=0.023$ ); social  
264 (84.1(24.1)vs.93.1(11.8), $P=0.048$ ); and total (69.1(25.2)vs.72.9(22.9), $P=0.007$ ) domains.  
265 Data from the MMQL QoL questionnaire showed improvements in the school domain  
266 (time2vs.time3) (69.1(25.2)vs.79.3(21.6), $P=0.034$ ). The MMQL also identified  
267 significant improvements in the physical health domain 12 months after the start of the 6-  
268 month exercise intervention (time2vs.time 4) 66.4(25.3)vs.79.4(16.7), $P=0.029$ ), but not  
269 immediately after the exercise intervention (time2vs.time3).

**270 Discussion**

271 This study reports a successfully implemented 6-month combined resistance and aerobic  
272 exercise intervention programme in young people after HSCT/TBI and demonstrated  
273 improved outcomes for insulin resistance, cardiorespiratory fitness, and some aspects of  
274 QoL.

275 Cardiorespiratory fitness ( $\dot{V}O_2\text{peak}$  mL/min/kg) was lower at baseline than predicted  
276 values for age and sex in UK children<sup>17</sup>.  $\dot{V}O_2\text{peak}$  is closely correlated to lean body mass,  
277 therefore, expressing  $\dot{V}O_2\text{peak}$  relative to body mass (rather than lean body mass) may be  
278 expected to show reduced  $\dot{V}O_2\text{peak}$  in HSCT/TBI survivors due to their abnormal body

*Exercise intervention paper final version PBC*

279 composition with reduced lean mass and increased adiposity. GHD also reduces  
280 cardiorespiratory fitness, and GH treatment improves cardiorespiratory fitness and body  
281 composition but not strength in adults with GHD<sup>44</sup>. All study participants had been  
282 established on GH treatment for at least 6 months prior to baseline assessment (time1) to  
283 control for the effects of GH with usual activity before the exercise programme.  
284 There were no changes in cardio-respiratory fitness, body composition or insulin  
285 resistance during the six month period before the intervention. There was a significant  
286 improvement in cardiorespiratory fitness seen during the exercise intervention. This may  
287 have been a larger effect due to reduced baseline cardiorespiratory fitness, related, in part,  
288 to de-conditioning from treatment. Significant improvement in Pulse O<sub>2</sub> suggests  
289 improved circulatory efficiency. VT occurred at mean(SD) 72(11.9)% $\dot{V}O_2$ peak. This  
290 refers to the point where aerobic metabolism is supplemented by anaerobic mechanisms  
291 during progressive exercise. In healthy adults, published data suggests VT occurs  
292 between 45-65%  $\dot{V}O_2$ peak. In the study group, there was no change in VT expressed as a  
293 percentage of  $\dot{V}O_2$ peak, however, as  $\dot{V}O_2$ peak increased significantly after the exercise  
294 intervention, VT occurred at a higher  $\dot{V}O_2$ . VT as % $\dot{V}O_2$ peak is known to be increased in  
295 GH deficient adults (73%) and contributes to fatigue during activities of daily living<sup>44 45</sup>.  
296 The improvements seen in  $\dot{V}O_2$ peak without a change in %VT may still improve fatigue.  
297 There were significant gains in leg and chest strength identified by the 1RM tests. This is  
298 not seen with GH treatment alone<sup>44</sup>, consistent with the lack of change seen during the  
299 run in period, and both GH treatment and exercise are required to regain full strength and  
300 fitness in GHD participants.

*Exercise intervention paper final version PBC*

301 A reduction in fat mass, an increase in lean mass or a reduction in percentage body fat  
302 may be expected to contribute to enhanced cardiorespiratory fitness and muscular  
303 strength, but significant changes in body composition were not seen during the 6-month  
304 training period. It may be that a larger sample, a longer intervention period, and/or longer  
305 follow-up are required to identify significant changes in body composition.

306 As expected, the study group demonstrated higher HOMA-IR values at baseline  
307 compared to published normal data for adults and adolescents. In >1000 US adolescents,  
308 two thirds of whom had normal BMI, the mean(SEM) HOMA-IR for girls was  
309 2.93(0.11)vs.2.82(0.11) for boys<sup>46</sup>. These data are comparable for the male study  
310 participants whereas the female participants had a higher HOMA-IR. HSCT/TBI has  
311 been shown to be associated with increased abdominal adiposity and diabetes risk, related  
312 both to increased insulin resistance and reduced  $\beta$ -cell function<sup>7</sup>. Body composition after  
313 HSCT/TBI is abnormal with increased visceral and intra-muscular fat and reduced  
314 subcutaneous fat and lean mass<sup>7</sup>: this might specifically contribute to development of the  
315 metabolic syndrome and insulin resistance due to a failure of the adipose tissue to  
316 expand, as seen in lipodystrophy<sup>47</sup>. It is also well known that increased insulin resistance  
317 is associated with central adiposity, and with GHD and GH replacement both in adults  
318 and children<sup>48 49</sup>. All participants were receiving GH replacement therapy for the duration  
319 of the study, potentially impacting on baseline insulin and HOMA-IR levels, but this  
320 cannot have influenced the improvement in insulin resistance with exercise as GH  
321 treatment remained constant throughout. The significant reductions in insulin and  
322 HOMA-IR recorded during the exercise intervention are consistent with other reports of  
323 reduced insulin resistance with either aerobic<sup>18</sup> or resistance training<sup>50 51</sup>.

*Exercise intervention paper final version PBC*

324 Previous studies have also reported improvements in insulin resistance without body  
325 composition changes<sup>52</sup> suggesting that initial improvements relate to improved metabolic  
326 function of muscle. The mechanisms whereby exercise improves insulin resistance are  
327 complex<sup>53 54</sup> and were not directly measured in this study. Both insulin and exercise  
328 promote an increase in glucose uptake in skeletal muscle, and involve an increase in  
329 translocation of the main glucose transporter protein (GLUT-4) from the intracellular  
330 space to the cell membrane<sup>55</sup>. However, insulin and exercise have been shown to act  
331 through different pathways, enabling insulin resistant individuals to increase glucose  
332 uptake with exercise. There is evidence that improvements in insulin sensitivity  
333 associated with exercise training are also related to changes in the expression and/or  
334 activity of proteins involved in insulin signal transduction in skeletal muscle such as the  
335 AMP-activated protein kinase (AMPK) and the protein kinase B (Akt) substrate AS160<sup>56</sup>.  
336 Increased lipid oxidation and/or turnover related to upregulation of the oxidative capacity  
337 of skeletal muscle and the expression of proteins involved in mitochondrial biogenesis is  
338 likely to be a further mechanism improving insulin sensitivity with training<sup>57</sup>, Significant  
339 gender differences were seen in the study with higher insulin and HOMA-IR in females,  
340 consistent with increased body fat and greater incidence of insulin resistance in females  
341 during childhood and adolescence<sup>58 59 60</sup>. However, obese adolescent and adult males  
342 have a greater risk of type 2 diabetes mellitus (T2DM) and of the metabolic syndrome  
343 than obese females due to greater visceral fat<sup>61 62</sup>. Female participants in this study had  
344 greater visceral adiposity than males and also higher body fat than published data for  
345 normal UK females of the same age. The use of oestrogen replacement therapy for  
346 treatment-related ovarian failure after HSCT/TBI in females may be a factor and

*Exercise intervention paper final version PBC*

347 untreated premature ovarian failure is itself associated with increased metabolic disease<sup>63</sup>.  
348 Oral hormone replacement therapy (HRT) may promote a greater increase in insulin  
349 resistance than trans-dermal HRT but data supporting this are typically from studies in  
350 older post-menopausal women and may not be applicable to young women with  
351 premature ovarian failure<sup>64 65</sup>.

352 The general health domain of SF-36 showed significant improvement during the exercise  
353 intervention and during the 6-month follow-up period. The magnitude of this  
354 improvement, however, was less than 1 SD: the size of a change usually accepted as  
355 conferring clinical relevance. Although this improvement is positive and consistent  
356 with what would be expected with exercise training in young people, the SF-36 may not  
357 be a sensitive enough tool in this sample size to detect a clinically relevant change. In  
358 addition the young people in this study reported higher QoL scores than those typically  
359 seen in adults and therefore a positive change may be more difficult to detect Other SF-  
360 36 domains showed significant improvements before the exercise intervention started  
361 (time1-time2). This suggests that taking part in the study, rather than the specific effects of  
362 the exercise intervention, was of benefit, or that there was familiarisation with the  
363 questionnaire between the time points. MMQL data showed significant improvements in  
364 the school domain during the exercise intervention, and MMQL physical health and  
365 school domains also improved between time 2 and time 4, but it is not clear whether this  
366 can be attributed to the exercise intervention alone. A number of studies employing  
367 exercise interventions have shown improvements in QoL in healthy participants<sup>66</sup>, cancer  
368 patients on therapy<sup>67 68</sup>, and cancer survivors<sup>69</sup>. The stated rationales include  
369 improvements in fitness, self-esteem, body image and resistance to fatigue.

*Exercise intervention paper final version PBC*

370 There are some limitations of this study. It was not practical to apply the whole study,  
371 including the intervention, to a control group but the longitudinal design controlled for  
372 the effects of growth and growth hormone over the baseline period. One question is  
373 whether there could be a bias to the more motivated individuals completing the study.  
374 However, we found that reasons for not completing the study were illness and moving  
375 out of the area which were unrelated to motivation. In addition the participants gave very  
376 positive feedback regarding taking part, which is supported by the positive findings in the  
377 QoL scores across the baseline period.

378 Summary: Survivors of HSCT/TBI in childhood were shown to have reduced  
379 cardiorespiratory fitness, associated with increased adiposity and de-conditioning. Female  
380 survivors were more affected than males at baseline, exhibiting increased insulin  
381 resistance and greater visceral fat. A 6-month combined resistance and aerobic exercise  
382 programme resulted in positive changes in cardiorespiratory fitness, measures of insulin  
383 resistance and some measures of QoL without changes in body composition. These data  
384 support the use of physical rehabilitation programmes to reduce metabolic and  
385 cardiovascular risk in HSCT/TBI survivors.

*Exercise intervention paper final version PBC*

386

387 **Compliance with Ethical Standards:**

388 ND received research grants for this study from Above and Beyond Charitable Trustees  
389 and Novonordisk. All of the authors declare that they have no conflict of interest.

390 Ethical approval: All procedures performed in studies involving human participants were  
391 in accordance with the ethical standards of the institutional and/or national research  
392 committee and with the 1964 Helsinki declaration and its later amendments or  
393 comparable ethical standards.

394 Informed consent: Informed consent was obtained from all individual participants  
395 included in the study and was properly documented.

396 Acknowledgements: Educational grants received by Novonordisk and Above and Beyond  
397 Charitable Trustees.

398 Data Availability statement: The data that support the findings of *this study are available from*  
399 *the corresponding author upon reasonable request.*

400

401

402

403 **References**

- 404 1. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and  
405 cardiovascular events in survivors of hematopoietic cell transplantation: a report  
406 from the bone marrow transplantation survivor study. *Blood*. 2007;109(4):1765-  
407 1772. doi:10.1182/blood-2006-05-022335
- 408 2. Hayden PJ, Keogh F, Conghaile MN, et al. A single-centre assessment of long-  
409 term quality-of-life status after sibling allogeneic stem cell transplantation for  
410 chronic myeloid leukaemia in first chronic phase. *Bone Marrow Transplant*.  
411 2004;34(6):545-556. doi:10.1038/sj.bmt.1704638
- 412 3. Neville K a, Cohn RJ, Steinbeck KS, Johnston K, Walker JL. Hyperinsulinemia,  
413 impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer:  
414 prevalence and risk factors. *J Clin Endocrinol Metab*. 2006;91(11):4401-4407.  
415 doi:10.1210/jc.2006-0128
- 416 4. Nysom K, Holm K, Michaelsen KF, et al. Degree of fatness after allogeneic BMT  
417 for childhood leukaemia or lymphoma. *Bone Marrow Transplant*. 2001;27(8):817-  
418 820. doi:10.1038/sj.bmt.1703012
- 419 5. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired  
420 glucose tolerance and dyslipidaemia as late effects after bone-marrow  
421 transplantation in childhood. *Lancet*. 2000;356(9234):993-997.  
422 doi:10.1016/S0140-6736(00)02717-3
- 423 6. Meacham LR, Sklar CA, Li S, et al. Diabetes mellitus in long-term survivors of  
424 childhood cancer. Increased risk associated with radiation therapy: a report for the  
425 childhood cancer survivor study. *Arch Intern Med*. 2009;169(15):1381-1388.



*Exercise intervention paper final version PBC*

- 426           doi:10.1001/archinternmed.2009.209
- 427   7.   Wei C, Thyagarajan M, Hunt L, et al. Reduced beta-cell reserve and pancreatic  
428       volume in survivors of childhood acute lymphoblastic leukaemia treated with bone  
429       marrow transplantation and total body irradiation. *Clin Endocrinol (Oxf)*.  
430       2015;82(1):59-67. doi:10.1111/cen.12575
- 431   8.   Gregory JW. Metabolic disorders. *Endocr Dev*. 2009;15:59-76.  
432       doi:10.1159/000207610
- 433   9.   Parsons SK, Phipps S, Sung L, Baker KS, Pulsipher MA, Ness KK. NCI,  
434       NHLBI/PBMTTC First International Conference on Late Effects after Pediatric  
435       Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,  
436       and Neurocognitive Outcomes. *Biol Blood Marrow Transplant*. 2012.  
437       doi:10.1016/j.bbmt.2011.12.501
- 438   10.   Warner JT, Bell W, Webb DKH, Gregory JW. Relationship between  
439       cardiopulmonary response to exercise and adiposity in survivors of childhood  
440       malignancy. *Arch Dis Child*. 1997;76(4):298-303. doi:10.1136/adc.76.4.298
- 441   11.   Warner JT. Body composition, exercise and energy expenditure in survivors of  
442       acute lymphoblastic leukaemia. *Pediatr Blood Cancer*. 2008;50(S2):456-461.  
443       doi:10.1002/pbc.21411
- 444   12.   Mello M, Tanaka C, Dullely FL. Effects of an exercise program on muscle  
445       performance in patients undergoing allogeneic bone marrow transplantation. *Bone  
446       Marrow Transplant*. 2003;32(7):723-728. doi:10.1038/sj.bmt.1704227
- 447   13.   San Juan AF, Chamorro-Vina C, Moral S, et al. Benefits of intrahospital exercise  
448       training after pediatric bone marrow transplantation. *Int J Sports Med*.

*Exercise intervention paper final version PBC*

- 449 2008;29(5):439-446. doi:10.1055/s-2007-965571
- 450 14. San Juan AF, Fleck SJ, Chamorro-Viña C, et al. Early-phase adaptations to  
451 intrahospital training in strength and functional mobility of children with leukemia.  
452 *J Strength Cond Res.* 2007;21(1):173-177. doi:10.1519/00124278-200702000-  
453 00031
- 454 15. Dimeo F, Bertz H, Finke J, Fetscher S, Mertelsmann R, Keul J. An aerobic  
455 exercise program for patients with haematological malignancies after bone marrow  
456 transplantation. *Bone Marrow Transplant.* 1996;18(6):1157-1160.  
457 <http://www.ncbi.nlm.nih.gov/pubmed/8971388>.
- 458 16. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated  
459 cardiovascular risks: results from large scale efficacy trials. *Obesity (Silver  
460 Spring).* 2009;17 Suppl 3(December):S43-S48. doi:10.1038/oby.2009.388
- 461 17. Winsley RJ, Armstrong N, Middlebrooke AR, Ramos-Ibanez N, Williams C a.  
462 Aerobic fitness and visceral adipose tissue in children. *Acta Paediatr.*  
463 2006;95(April 2005):1435-1438. doi:10.1080/08035250600643244
- 464 18. O'Donovan G, Kearney EM, Nevill AM, Woolf-May K, Bird SR. The effects of  
465 24 weeks of moderate- or high-intensity exercise on insulin resistance. *Eur J Appl  
466 Physiol.* 2005;95(5-6):522-528. doi:10.1007/s00421-005-0040-5
- 467 19. Fagard RH. Effects of exercise, diet and their combination on blood pressure. *J  
468 Hum Hypertens.* 2005;19(SUPPL. 3). doi:10.1038/sj.jhh.1001956
- 469 20. Fagard RH. Exercise is good for your blood pressure: Effects of endurance training  
470 and resistance training. In: *Clinical and Experimental Pharmacology and  
471 Physiology.* Vol 33. ; 2006:853-856. doi:10.1111/j.1440-1681.2006.04453.x

*Exercise intervention paper final version PBC*

- 472 21. Park S-K, Park J-H, Kwon Y-C, Kim H-S, Yoon M-S, Park H-T. The Effect of  
473 Combined Aerobic and Resistance Exercise Training on Abdominal Fat in Obese  
474 Middle-aged Women. *J Physiol Anthropol Appl Human Sci.* 2003;22(3):129-135.  
475 doi:10.2114/jpa.22.129
- 476 22. Umpierre D, Stein R. Hemodynamic and vascular effects of resistance training:  
477 implications for cardiovascular disease. *Arq Bras Cardiol.* 2007;89(4):256-262.
- 478 23. Faigenbaum A. Resistance Exercise and Youth: Survival of the Strongest. *Pediatr*  
479 *Exerc Sci.* 2017;29(1):14-18. doi:10.1123/pes.2016-0262
- 480 24. Faigenbaum AD, Kraemer WJ, Blimkie CJR, et al. Youth Resistance Training:  
481 Updated Position Statement Paper From the National Strength and Conditioning  
482 Association. *J Strength Cond Res.* 2009;23:S60-S79.  
483 doi:10.1519/JSC.0b013e31819df407
- 484 25. Wei C, Thyagarajan MS, Hunt LP, Shield JPH, Stevens MCG, Crowne EC.  
485 Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell  
486 transplantation is associated with lipodystrophic and sarcopenic phenotypes. *Pediatr*  
487 *Blood Cancer.* 2015. doi:10.1002/pbc.25601
- 488 26. Deepak D, Daousi C, Javadpour M, et al. The influence of growth hormone  
489 replacement on peripheral inflammatory and cardiovascular risk markers in adults  
490 with severe growth hormone deficiency. *Growth Horm IGF Res.* 2010;20(3):220-  
491 225. doi:10.1016/j.ghir.2010.02.002
- 492 27. Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts  
493 cardiovascular risk in young adults treated for acute lymphoblastic leukemia in  
494 childhood. *J Clin Endocrinol Metab.* 2004;89(10):5003-5012.

*Exercise intervention paper final version PBC*

- 495           doi:10.1210/jc.2004-0126
- 496 28.   Keohane DM, Woods T, O'Connor P, et al. Four men in a boat: Ultra-endurance  
497       exercise alters the gut microbiome. *J Sci Med Sport*. 2019.  
498       doi:10.1016/j.jsams.2019.04.004
- 499 29.   De Onis M, Onyango AW. WHO child growth standards. *Lancet*. 2008;371:204.  
500       doi:10.1016/S0140-6736(08)60131-2
- 501 30.   Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight,  
502       height velocity, weight velocity, and stages of puberty. *Arch Dis Child*.  
503       1976;51(3):170-179. doi:10.1136/adc.51.3.170
- 504 31.   Tj C, Jv F, Ma P. Body mass index reference curves for the. *UK, 1990 Arch Dis*  
505       *Child*. 1995.
- 506 32.   Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood  
507       cancer survivors: A report from the childhood cancer survivor study. *J Clin Oncol*.  
508       2009;27(14):2396-2404. doi:10.1200/JCO.2008.21.1433
- 509 33.   McMillan C V, Bradley C, Gibney J, Russell-Jones DL, Sönksen PH. Evaluation  
510       of two health status measures in adults with growth hormone deficiency. *Clin*  
511       *Endocrinol (Oxf)*. 2003;58(4):436-445. doi:10.1046/j.1365-2265.2003.01736.x
- 512 34.   Bhatia S, Jenney MEM, Bogue MK, et al. The Minneapolis-Manchester quality of  
513       life instrument: Reliability and validity of the adolescent form. *J Clin Oncol*.  
514       2002;20(24):4692-4698. doi:10.1200/JCO.2002.05.103
- 515 35.   Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling.  
516       *Diabetes Care*. 2004;27(6):1487-1495. doi:10.2337/diacare.27.6.1487
- 517 36.   Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all

*Exercise intervention paper final version PBC*

- 518 ages: A new approach. *Am J Respir Crit Care Med.* 2008;177(3):253-260.  
519 doi:10.1164/rccm.200708-1248OC
- 520 37. Marinov B, Kostianev S, Turnovska T. Modified treadmill protocol for evaluation  
521 of physical fitness in pediatric age group--comparison with Bruce and Balke  
522 protocols. *Acta Physiol Pharmacol Bulg.* 2003;27(2-3):47-51.
- 523 38. Tolfrey K, Barker A, Thom JM, Morse CI, Narici M V, Batterham AM. Scaling of  
524 maximal oxygen uptake by lower leg muscle volume in boys and men. *J Appl  
525 Physiol.* 2006;100(6):1851-1856. doi:10.1152/jappphysiol.01213.2005
- 526 39. Armstrong N, Welsman JR. Assessment and interpretation of aerobic fitness in  
527 children and adolescents. *Exerc Sport Sci Rev.* 1994;22:435-476.
- 528 40. Armstrong N, Williams J, Balding J, Gentle P, Kirby B. The peak oxygen uptake  
529 of British children with reference to age, sex and sexual maturity. *Eur J Appl  
530 Physiol Occup Physiol.* 1991. doi:10.1007/BF00634975
- 531 41. Beaver, W. L., Wasserman, K. and Whipp BJ. 'A new method for detecting  
532 anaerobic threshold by gas exchange. *J Appl Physiol.* 1986;60(6):2020-2027.
- 533 42. McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves  
534 for children. *Int J Obes.* 2006. doi:10.1038/sj.ijo.0803232
- 535 43. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio  
536 Heart Study. *Diabetes Care.* 1997;20(7):1087-1092.  
537 doi:10.2337/diacare.20.7.1087
- 538 44. Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S. The influence of growth  
539 hormone status on physical impairments, functional limitations, and health-related  
540 quality of life in adults. *Endocr Rev.* 2006;27(3):287-317. doi:10.1210/er.2004-

*Exercise intervention paper final version PBC*

- 541 0022
- 542 45. Woodhouse LJ, Asa SL, Thomas SG, Ezzat S. Measures of submaximal aerobic  
543 performance evaluate and predict functional response to growth hormone (GH)  
544 treatment in GH-deficient adults. *J Clin Endocrinol Metab.* 1999;84(12):4570-  
545 4577. doi:10.1210/jc.84.12.4570
- 546 46. Cummings DM, Dubose KD, Imai S, Collier DN. Fitness versus fatness and  
547 insulin resistance in U.S. Adolescents. *J Obes.* 2010;2010.  
548 doi:10.1155/2010/195729
- 549 47. Ablamunits V, Weisberg SP, Lemieux JE, Combs TP, Klebanov S. Reduced  
550 adiposity in ob/ob mice following total body irradiation and bone marrow  
551 transplantation. *Obesity.* 2007;15(6):1419-1429. doi:10.1038/oby.2007.170
- 552 48. Liang L, Zou C, Li Y, et al. [Effect of recombinant human growth hormone on  
553 glucose metabolism in children with growth hormone deficiency]. *Zhonghua er ke  
554 za zhi = Chinese J Pediatr.* 2006;44(9):657-661.
- 555 49. Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth hormone (GH)  
556 treatment on bone in postpubertal GH-deficient patients: A 2-year randomized,  
557 controlled, dose-ranging study. *J Clin Endocrinol Metab.* 2003;88(9):4124-4129.  
558 doi:10.1210/jc.2003-030126
- 559 50. Winett RA, Carpinelli RN. Potential health-related benefits of resistance training.  
560 *Prev Med (Baltim).* 2001;33(5):503-513. doi:10.1006/pmed.2001.0909
- 561 51. Irvine C, Taylor NF. Progressive resistance exercise improves glycaemic control in  
562 people with type 2 diabetes mellitus: a systematic review. *Aust J Physiother.*  
563 2009;55(4):237-246. doi:10.1016/S0004-9514(09)70003-0

*Exercise intervention paper final version PBC*

- 564 52. Shaibi GQ, Cruz ML, Ball GDC, et al. Effects of resistance training on insulin  
565 sensitivity in overweight Latino adolescent males. *Med Sci Sports Exerc.*  
566 2006;38(7):1208-1215. doi:10.1249/01.mss.0000227304.88406.0f
- 567 53. Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action.  
568 In: *Acta Physiologica.* Vol 192. ; 2008:127-135. doi:10.1111/j.1748-  
569 1716.2007.01783.x
- 570 54. Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms  
571 regulating glucose uptake in skeletal muscle. *Adv Physiol Educ.* 2014;38(4):308-  
572 314. doi:10.1152/advan.00080.2014
- 573 55. Goodyear, PhD LJ, Kahn, MD BB. EXERCISE, GLUCOSE TRANSPORT, AND  
574 INSULIN SENSITIVITY. *Annu Rev Med.* 1998;49(1):235-261.  
575 doi:10.1146/annurev.med.49.1.235
- 576 56. Goodyear LJ. AMP-activated protein kinase: a critical signaling intermediary for  
577 exercise-stimulated glucose transport? *Exerc Sport Sci Rev.* 2000;28(3):113-116.
- 578 57. Fisher JS. Potential Role of the AMP-activated Protein Kinase in Regulation of  
579 Insulin Action. *Cellscience.* 2006;2(3):68-81.
- 580 58. Wisniewski AB, Chernausk SD. Gender in childhood obesity: Family  
581 environment, hormones, and genes. *Gend Med.* 2009;6(SUPPL. 1):76-85.  
582 doi:10.1016/j.genm.2008.12.001
- 583 59. Murphy MJ, Metcalf BS, Voss LD, et al. Girls at five are intrinsically more insulin  
584 resistant than boys: The Programming Hypotheses Revisited--The EarlyBird Study  
585 (EarlyBird 6). *Pediatrics.* 2004;113(1 Pt 1):82-86. doi:10.1542/peds.113.1.82
- 586 60. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH. Gender and Tanner stage

*Exercise intervention paper final version PBC*

- 587 differences in body composition and insulin sensitivity in early pubertal children. *J*  
588 *Clin Endocrinol Metab.* 1995;80(1):172-178. doi:10.1210/jcem.80.1.7829608
- 589 61. Shi H, Seeley RJ, Clegg DJ. Sexual differences in the control of energy  
590 homeostasis. *Front Neuroendocrinol.* 2009;30(3):396-404.  
591 doi:10.1016/j.yfrne.2009.03.004
- 592 62. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and  
593 energy balance. *Gend Med.* 2009;6(SUPPL. 1):60-75.  
594 doi:10.1016/j.genm.2009.02.002
- 595 63. Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L,  
596 Chrousos GP. Premature ovarian failure, endothelial dysfunction and estrogen-  
597 progestogen replacement. *Trends Endocrinol Metab.* 2006;17(3):101-109.  
598 doi:10.1016/j.tem.2006.02.003
- 599 64. Stevenson JC. Type and route of estrogen administration. *Climacteric.*  
600 2009;12(SUPPL. 1):86-90. doi:10.1080/13697130903007389
- 601 65. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE.  
602 Meta-analysis: Effect of hormone-replacement therapy on components of the  
603 metabolic syndrome in postmenopausal women. *Diabetes, Obes Metab.*  
604 2006;8(5):538-554. doi:10.1111/j.1463-1326.2005.00545.x
- 605 66. Gillison FB, Skevington SM, Sato A, Standage M, Evangelidou S. The effects of  
606 exercise interventions on quality of life in clinical and healthy populations; a meta-  
607 analysis. *Soc Sci Med.* 2009;68(9):1700-1710.  
608 doi:10.1016/j.socscimed.2009.02.028
- 609 67. Ligibel J a, Partridge A, Giobbie-Hurder A, et al. Physical and psychological



*Exercise intervention paper final version PBC*

- 610 outcomes among women in a telephone-based exercise intervention during  
611 adjuvant therapy for early stage breast cancer. *J Womens Health (Larchmt)*.  
612 2010;19(8):1553-1559. doi:10.1089/jwh.2009.1760
- 613 68. Mustian KM, Peppone L, Darling T V, Palesh O, Heckler CE, Morrow GR. A 4-  
614 week home-based aerobic and resistance exercise program during radiation  
615 therapy: a pilot randomized clinical trial. *J Support Oncol*. 2009;7(5):158-167.
- 616 69. Speck RM, Gross CR, Hormes JM, et al. Changes in the body image and  
617 relationship scale following a one-year strength training trial for breast cancer  
618 survivors with or at risk for lymphedema. *Breast Cancer Res Treat*.  
619 2010;121(2):421-430. doi:10.1007/s10549-009-0550-7
- 620

*Exercise intervention paper final version PBC*

621 Legends;

622 **Figure 1. Mean (SD)  $\dot{V}O_2$  peak a time 1 to time 4 indicating an improvement in**  
623 **aerobic fitness following the exercise intervention (between time 2 and time 3).**

624 **Figure 2. Log HOMA-IR at time 1 to time 4 indicating improved insulin resistance**  
625 **after the exercise intervention (between time 2 and time 3).**

626 **Figure 3. Quality of life (QoL) scores at time 1 to time 4 indicating improved in QoL**  
627 **after the exercise intervention (between time 2 and time 3).**

628 **Table 1. Demographics and treatment details of participants Table 2. Changes in  $\dot{V}$**   
629  **$O_2$  max, Pulse  $O_2$ , percentage body fat and insulin resistance indicating significant**  
630 **improvements in outcomes after the exercise intervention (between time 2 and time**  
631 **3, pairwise comparisons 2 vs. 3).**

632 Normally distributed data is expressed as mean (standard deviation) whereas skewed  
633 data\* is expressed as geometric mean (range). Parametric data were compared overall  
634 using one-way analysis of variance (ANOVA) followed by pairwise comparisons using  
635 post-hoc Fisher's least significance difference (LSD) tests. Skewed data\* was log  
636 transformed to attain a normal distribution before parametric testing. Sample size in  
637 pairwise comparisons: 1 vs. 2 ( $n=24$ ), 2 vs. 3 ( $n=20$ ), 3 vs. 4 ( $n=16$ ). Statistically  
638 significant  $P$  values are shown in bold.

639

**Table 1. Demographics and treatment details of participants**

Demographics and treatments	number of participants	
Mean (range) age	24	16.7(10.9-24.5)yrs
Mean (range) times since HSCT/TBI	24	8.4(2.3-16.0)yrs
Conditioning cyclophosphamide	24	total dose 120mg/kg
Conditioning campath	24	total dose 50mg
Conditioning TBI	24	total dose 14.4Gy; 8 fractions
CNS boost irradiation	8	6Gy; 4 fractions
Previous cranial irradiation	2	18Gy and 24Gy
GVHD post-transplant	12	oral steroids ( <i>n</i> =6) topical steroids ( <i>n</i> =6)
Dose of GH treatment for GHD	24	children 5mg/m <sup>2</sup> /week adolescents 6.5mg/m <sup>2</sup> /week transition 0.6-1.0mg daily
Thyroxine	6	
Oestrogen	8/10 females	
Testosterone	5/14 males	
Pubertal status	2 pre-pubertal, 5 pubertal 13 post-pubertal.	

Haemopoietic stem cell transplantation (HSCT/TBI), central nervous system (CNS), graft versus host disease (GVHD), growth hormone (GH), growth hormone deficiency (GHD).

**TABLE 2. Demonstrating Changes in  $\dot{V}O_2$ peak, Pulse  $O_2$ , Body Composition and Insulin Resistance**

Outcome measure	Mean (SD) or Geometric mean (range)*				ANOVA <i>P</i> value	Pairwise comparison: <i>P</i> value
	Time 1	Time 2	Time 3	Time 4		
$\dot{V}O_2$ peak (L/min)	1.80 (0.70)	1.83 (0.57)	2.26 (1.04)	2.09 (1.01)	<b>0.002</b>	1 vs. 2: 0.29 <b>2 vs. 3: 0.020</b> 3 vs. 4: 0.78
$\dot{V}O_2$ peak/kg (mL/min/kg)	35.7 (11.8)	35.7 (8.9)	41.7 (16.1)	38.4 (8.1)	0.20	1 vs. 2: 0.87 <b>2 vs. 3: 0.05</b> 3 vs. 4 (0.46)
Pulse $O_2$ (mL/beat/min)	9.8 (3.0)	10.1 (2.8)	12.2 (4.8)	10.8 (5.1)	<b>0.036</b>	1 vs. 2: 0.76 <b>2 vs. 3: 0.026</b> 3 vs. 4: 0.61
Fat mass (kg)	16.62 (11.26)	16.44 (11.39)	15.87 (11.43)	16.30 (11.67)	0.997	1 vs. 2: 0.96 2 vs. 3: 0.86 3 vs. 4: 0.91
Lean mass (kg)	31.58 (7.22)	34.67 (9.14)	35.70 (9.67)	36.72 (10.83)	0.323	1 vs. 2: 0.26 2 vs. 3: 0.71 3 vs. 4: 0.74
Percentage body fat	31.1 (15.0)	29.5 (13.9)	28.3 (14.0)	26.6 (13.2)	0.27	1 vs. 2: 0.76 2 vs. 3: 0.83 3 vs. 4: 0.20

BMISDS	-0.07 (1.63)	-0.08 (1.53)	-0.28 (1.68)	-0.40 (1.79)	<b>0.07</b>	1 vs. 2: 0.93 <b>2 vs. 3: 0.03</b> 3 vs. 4: 0.41
Fasted Plasma Insulin* (mIU/L)	13.84 (2.61- 68.30)*	16.56 (1.48- 72.80)*	12.62 (1.04- 54.97)*	11.93 (0.84- 80.38)*	<b>0.050</b>	1 vs. 2: 0.13 <b>2 vs. 3: 0.03</b> 3 vs. 4: 0.60
HOMA-IR*	3.00 (0.53- 18.31)*	3.65 (0.30- 17.26)*	2.72 (0.22- 12.89)*	2.67 (0.20- 16.67)*	0.77	1 vs. 2: 0.24 <b>2 vs. 3: 0.02</b> 3 vs. 4: 0.06

Peak rate of oxygen uptake ( $\dot{V}O_{2\text{peak}}$ ), rate of oxygen uptake per heart beat (Pulse  $O_2$ ), standard deviation (SD), body mass index standard deviation score (BMISDS), homeostatic model assessment of insulin resistance (HOMA-IR), repeated measures analysis of variance (ANOVA). Normally distributed data is expressed as mean (SD) whereas skewed data\* is expressed as geometric mean (range). Parametric data were compared overall using repeated ANOVA followed by pairwise comparisons using post-hoc Fisher's least significance difference (LSD) tests. Skewed data\* was log transformed to attain a normal distribution before parametric testing. Sample size in pairwise comparisons: 1 vs. 2 ( $n=24$ ), 2 vs. 3 ( $n=20$ ), 3 vs. 4 ( $n=16$ ). Statistically significant  $P$  values are shown in bold





